Singapore, Dec. 10 -- China's Fosun Pharma announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. have entered into an exclusive collaboration and license agreement.

Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialisation of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient.

The license covers all indications for therapeutic, diagnostic, and prophylactic human and veterinary use. Under the terms of the agreement, Yao Phar...